

DEVELOPMENT AND VALIDATION OF SPECTROSCOPIC METHODS FOR THE ESTIMATION OF VILAZODONE IN BULK AND IN TABLET FORMULATION

Redasani Vivekkumar K*, Chhajed Chetan F, Patil Pritam D, Surana Sanjay J.

Department of Pharmaceutical Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research, Karwand Naka, Shirpur Dist. Dhule- 425 405 (MS) India. Tel/fax: +912563255189 Cell: +919822027806

Received on : 20.02.2014

Revised : 03.03.2014

Accepted : 15.03.2014

ABSTRACT


Two rapid, specific and economic methods have been developed using methanol as solvent for spectrophotometric determination of vilazodone HCl in bulk and in tablet formulation. Vilazodone HCl showed maximum absorption at 241nm (method A) and same spectrum was derivatised into first order derivative at $\lambda_{\text{max}}=2$; amplitude of trough was recorded at 246nm (method B). In both methods vilazodone HCl follows linearity in concentration range 1-6 $\mu\text{g/ml}$ and exhibited good correlation coefficient ($r^2=0.999$) and excellent mean recovery (98.32%) and (99.53%). The methods were validated statistically and by recovery studies for linearity, precision, repeatability, and reproducibility. The obtained results proved that both the methods can be employed for routine analysis of vilazodone HCl in bulks as well as in the commercial tablet formulation.

Keywords: Vilazodone HCl; UV spectroscopy; derivative spectroscopy; validation.

INTRODUCTION

Vilazodone HCl (VLN, Fig. 1) is chemically 5-(4-[4-(5-cyano-1*H*-indol-3-yl)butyl] piperazin-1-yl) benzofuran-2-carboxamide hydrochloride¹. It contains an indole-piperazine that utilizes its function as an SSRI and 5-HT_{1a} receptor partial agonist². It belongs to the category of serotonergic antidepressant approved by FDA (Food and Drug Administration) for treatment of depressive disorder^{3, 4}. It is a novel serotonin reuptake inhibitor and serotonin 1A receptor partial agonist⁵ having strong affinity for D2 dopaminergic receptors⁶. It has actions at several 5-HT (serotonin) receptor subtypes^{7,8}. Thus, at the moment, available literature only highlights therapeutic and pharmacological profile of drug but no published methods validated for its estimation in pharmaceutical formulations.

Fig. 1: Chemical structure of Vilazodone HCl



This encourages undertaking this work, so that quantitative estimation of VLN can be done and hence can be used for routine analysis of bulk and tablet formulation as well. Revolutionary efforts are undertaken

for the first time to develop and validate rapid, simple, specific, sensitive, accurate and precise spectroscopic methods for the determination of VLN in bulk and in tablet dosage form. This preliminary successful approach also motivated us to extend the work developing HPLC method which might be undertaken in due course of time.

EXPERIMENTAL

Reagents and chemicals

Vilazodone HCl was supplied as a gift sample by Glenmark Pharmaceuticals Ltd., Mumbai (India). All chemicals and reagents used were of analytical grade. Methanol was selected as the solvent for sample preparation.

Instrument

A double beam UV-Visible spectrophotometer (UV-2450, Shimadzu, Japan; software UVProbe2.21) with specific measurements, using a pair of 10mm matched quartz cells. All weights were taken on electronic balance (Shimadzu AUX 120).

Preparation of Standard stock solutions

Accurately weighed 10 mg of VLN transferred to 100 ml volumetric flasks. It was dissolved in methanol and volume was made up to the mark with same solvent to obtain final strength 100 $\mu\text{g/ml}$.

Method-A UV Spectrophotometry⁹

From the stock solution dilution was made in order to get the concentration of 3 $\mu\text{g/ml}$. The solution was

*Correspondence : vivek.redasani@gmail.com

Spectrophotometric estimation of vilazodone

scanned in the UV range of 200-400 nm; VLN showed absorbance maximum at 241nm (Fig. 2).




Fig. 2: Simple UV spectrum of VLN in methanol showing λ max at 241 nm

Method-B First Order Derivative Method⁹

The zero order derivative spectra of concentration 3 $\mu\text{g}/\text{ml}$ were derivatised into first order using UV probe software of the spectrophotometer; amplitude of the trough was recorded at 246nm (Fig. 3).




Fig. 3: First order derivative spectrum of VLN in methanol showing amplitude at 246 nm

Redasani Vivekkumar K *et al.*

Analysis of tablet formulation

Twenty tablets were accurately weighed, powdered and the quantity equivalent to 10 mg of VLN was transferred to a 100ml volumetric flask and volume made up to 50ml with methanol and sonicated for 20 min. The solution was filtered through Whatman filter paper no. 41 and the resultant solution was diluted with same solvent to get final concentration 5 $\mu\text{g}/\text{ml}$ for both methods. The amount of drug present in sample solution was determined using the calibration curve of standard drug.

Validation of proposed method⁹

Linearity

Appropriate known volumes of aliquots from standard VLN stock solution were transferred to series of six 10 ml volumetric flasks. The volume was adjusted to the mark with methanol to get concentrations of 1-6 $\mu\text{g}/\text{ml}$ for both methods. Calibration curve was plotted for both methods as absorbance vs concentration (Fig. 4) and concentration vs amplitude (Fig. 5).




Fig. 4: Calibration curve of UV- spectrophotometry method of Vilazodone HCl




Fig. 5: Calibration curve of first order derivative method of Vilazodone HCl

Precision

Precision of the method was studied as intra-day and inter-day variations. Intra-day precision was determined by analyzing 2, 3 and 4 $\mu\text{g}/\text{ml}$ of VLN

Spectrophotometric estimation of vilazodone

solutions for three times on the same day. Inter-day precision was determined by analyzing 2, 3 and 4 µg/ml of VLN solutions daily for three consecutive days over a period of week.

Accuracy (Recovery studies)

To assess the accuracy of the proposed method, a known amount of standard stock solution was added at different levels i.e. 80, 100 and 120%, to the pre-analyzed sample solutions. The absorbance of solutions was recorded; results of recovery studies are reported in **Table 1**. High recovery and low standard deviation confirmed that proposed method is accurate for determination of VLN in pharmaceutical formulation.

Table 1: Summary of validation parameters for proposed methods

Parameters	Method A	Method B
Linearity (µg/ml)	1-6	1-6
$Y = mx + C$	$Y = 0.1895x + 0.0063$	$Y = 0.0378x + 0.0016$
Correlation coefficient	0.9996	0.9994
LOD (µg/ml)	0.112	0.150
LOQ (µg/ml)	0.341	0.454
% Recovery	98.32	99.53
% RSD	0.95	0.57
Precision (%RSD)		
Inter-Day	0.72-1.51	0.06-0.47
Intra-Day	0.05-1.83	0.03-0.35
Repeatability #	1.07	0.18
Ruggedness (%RSD) #		
Analyst I	1.12	0.18
Analyst II	1.70	0.81

*n = 3 #n = 6

Repeatability

Repeatability was determined by analyzing 3 µg/ml concentration of VLN solution for six times. The absorbance of solution was recorded and spectra were derivative.

Sensitivity

Sensitivity of the proposed method was estimated in terms of limit of detection (LOD) and limit of quantitation (LOQ). The LOD and LOQ were calculated by the use of equation, $LOD = SD/S \times 3.3$ and $LOQ = SD/S \times 10$, where SD is the residual standard deviation of the peak areas of the drug (n=6) and 'S' is the slope of the line. Sensitivity was performed between 2-3 µg/ml, for both spectroscopic methods.

Ruggedness

Ruggedness of the proposed method is determined by analysis of aliquots from homogenous slot by two different analysts using same operational and environmental conditions.

RESULTS AND DISCUSSION

VLN in methanol showed maximum absorbance at 241nm. The same spectrum was derivatized into first order derivative. In these methods VLN followed linearity in concentration range 1-6 µg/ml. The developed methods were applied for pharmaceutical formulations. The %amount of VLN from tablet formulation by method A and method B was found to be 100.18 % (RSD 0.52)

Redasani Vivekkumar K *et al.*

and 98.32% (RSD 0.45), respectively. The amount of VLN estimated by methods was found to be within acceptance criteria. The detailed results from validation of proposed methods are tabulated Table 1. Precision study at different time and day interval in both methods showed low standard deviation and % RSD less than 2 indicate that the proposed methods are precise for determination of VLN. High recovery and low standard deviation confirmed that proposed methods are accurate for determination in pharmaceutical formulation. Also these methods were rugged as low value of %RSD was obtained. Determination of LOD and LOQ indicates adequate sensitivity of the methods. Thus, both the methods are found to be simple, economical and can suitably apply for the routine analysis of vilazodone HCl in pharmaceutical tablet formulation.

ACKNOWLEDGEMENT

The authors are thankful to Glenmark Pharmaceuticals Ltd., Mumbai (India) for providing gift sample of vilazodone HCl.

REFERENCES

1. The Online Merck Index, Maryadele J. O' Neil. Editor 15th edn. Merck and Co, White House Station, NJ, USA, 2006, Monograph no.MONO1500010176.
2. Hughes ZA, *et al.* Neurochemical evaluation of the novel 5-HT_{1A} receptor partial agonist/serotonin reuptake inhibitor, vilazodone. *Eur J of Pharma.* 2005; 510(1-2): 49-57.
3. Khan A, *et al.* A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. *J Clin Psychiatry.* 2011; 72(4): 441-447.
4. Laugren TP, *et al.* Vilazodone: Clinical basis for the US food and Drug. *J Clin Psychiatry.* 2011;72 (9):1166-73.
5. Reuters. Anti-depressant, Forest Laboratories, viibryd (vilazodone), package insert. 2011.
6. Dawson L and Watson J. Vilazodone: a 5-HT_{1A} receptor agonist/serotonin transporter inhibitor for treatment of affective disorders, *CNS Neuroscience & Therapeutics.* 2009; 15: 107-17.
7. Traynor K, *et al.* Vilazodone approved for major depression, *Am J Health Syst Pharm.*, 2011; 68(5): 366.
8. Sorbera LA, *et al.* Vilazodone hydrochloride-Antidepressant-5-HT_{1A} partial agonist -5-HT reuptake inhibitor. *Drug Future.* 2001; 26, 247-252.
9. Becket AH, Stenlake JB. *Practical Pharmaceutical Chemistry*, New Delhi: C. B. S. Publications, 4th Edition: 2007, p 243-256.